about
Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL™ Sickle Cell Disease ModuleProvider Perspective on Integrative Medicine for Pediatric Sickle Cell Disease-related PainAAPT Diagnostic Criteria for Chronic Sickle Cell Disease Pain.A phase 1 dose-finding study of intravenous L-citrulline in sickle cell disease: a potential novel therapy for sickle cell pain crisis.Inhaled corticosteroid use to prevent severe vaso-occlusive episode recurrence in children between 1 and 4 years of age with sickle cell disease: a multicenter feasibility trial.Pain-measurement tools in sickle cell disease: where are we now?Hydroxyurea therapy in sickle cell disease: An alternative approach to preoperative red cell transfusion.Pain and opioid use after reversal of sickle cell disease following HLA-matched sibling haematopoietic stem cell transplant.Graph theory analysis reveals how sickle cell disease impacts neural networks of patients with more severe diseaseCharacteristics and outcomes of osteomyelitis in children with sickle cell disease: A 10-year single-center experienceAAAPT Diagnostic Criteria for Acute Sickle Cell Disease PainIdentification of red blood cell antibodies in maternal breast milk implicated in prolonged hemolytic disease of the fetus and newbornTricuspid Regurgitation Velocity and Other Biomarkers of Mortality in Children, Adolescents and Young Adults with Sickle Cell Disease in the United States: the PUSH StudyBridging the Gap Among Clinical Practice Guidelines for Pain Management in Cancer and Sickle Cell DiseaseTargeted Hydroxyurea Education after an Emergency Department Visit Increases Hydroxyurea Use in Children with Sickle Cell AnemiaProgressive loss of brain volume in children with sickle cell anemia and silent cerebral infarct: A report from the silent cerebral infarct transfusion trialPsychosocial and affective comorbidities in sickle cell disease
P50
Q33791528-C21F083A-8BDF-4EEB-9F4A-6C2C6EA08FB9Q36588817-3A5DA0E9-B6B7-42A2-8DF7-A7759E225435Q38773271-634D137E-7D9A-4BF7-833C-2A9877A45461Q48090580-5A15F6BF-64FD-455F-8899-F28C3A6D2C3EQ48264531-A052ECD8-099F-4BB8-9138-5E8614587313Q49988992-9FA1369A-DC53-4152-9F06-7009D740CA48Q50238221-B8DC9296-2090-47C5-9CBC-CF374F1DBD18Q52727247-B3CEAB23-94A4-4395-8C84-6F002626A1AFQ60297491-3950AC15-8688-4C51-BEA5-6478C3F8ACD3Q89742792-4B1B6388-D8FA-4500-94E2-FCC193D9B3A6Q90714730-2AB18663-50BC-4B25-94B4-698560F19C09Q91349817-31B0D219-F0DD-4E5F-86BE-19802B73F2A6Q91534900-34DDDCD2-3CD1-4500-BC30-CC3CBC2C67C1Q91629242-EA75E7CD-2815-4F00-B957-8778BBCCB885Q91716403-F66C9499-765D-4ECD-8ADA-38A064F70FDEQ91842481-0EC6EE35-9BDD-4B28-B4AC-76A565BCF7DEQ92971079-13A439E8-B439-4F7B-9F5E-7D4A2B124ADD
P50
description
researcher ORCID ID = 0000-0002-0698-2936
@en
wetenschapper
@nl
name
Deepika Darbari
@ast
Deepika Darbari
@en
Deepika Darbari
@es
Deepika Darbari
@nl
type
label
Deepika Darbari
@ast
Deepika Darbari
@en
Deepika Darbari
@es
Deepika Darbari
@nl
prefLabel
Deepika Darbari
@ast
Deepika Darbari
@en
Deepika Darbari
@es
Deepika Darbari
@nl
P31
P496
0000-0002-0698-2936